Mercy Hospital & Health Services Contact Us
About Mercy
Join Our Team
set font size large set font size medium set font size small
email this page print this page
Protecta Implantable Defribrillator Banner
Clinical Trials

Mercy Health - St. Vincent Medical Center
For Payments:
P.O Box 636447
Cincinnati, Ohio 45263-6447
For Assistance: (855) 847-6049

Study to Evaluate System Safety and Clinical Performance of the Protecta Implantable Cardioverter Defibrillator (ICD) Plus Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Sponsored by Medtronic Cardiac Rhythm Disease Management


The purpose of the study is two-fold. In Phase I (Protecta Clinical Study), system performance will be evaluated. In Phase II (PainFree SST), the inappropriate shock-free rate at one year of subjects implanted with a Medtronic Protecta implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) will be evaluated. Phase II of the study will begin when the Medtronic Protecta devices are market released in each participating geography. Subjects enrolled into Phase I of the study will continue follow up.


Criteria Inclusion Criteria:
  • Patients meeting one of the following criteria can be included in Phase I of the study:
    • Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D)
    • Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant)
  • Patients meeting one of the following criteria can be included in Phase II of the study:
    • Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device
    • Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D
    • Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant
Exclusion Criteria:
  • Patients with a mechanical tricuspid heart valve
  • Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study
  • Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients
  • Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc)
  • Patients anticipated not being able to complete the study
  • Patients unwilling to provide written informed consent

Contacts and Locations

Contacts Physicians:
Ameer Kabour, MD

Brenda Hoagland, RN, CCRC
Michelle Hickam, BSN
Julie Neidhardt, BSN

Please contact us at 419-251-4919 for more information about this study.
follow us online
facebook youtube

Contact us
Home  |  Sitemap

Disclaimer & Terms of Use  |  Privacy Statement  |  Notice of Privacy Practices
Copyright ©2016 Mercy. Last modified 10/14/2011